top of page
  • Action Against AMD

AAAMD Appoints Dr. Ton Rijnders to Board of Trustees

CEO Wen Hwa Lee and Chair of the Board Rob Bryan would like to welcome Dr. Ton Rijnders to the AAAMD Board of Trustees.

Ton Rijnders holds a PhD in molecular biology. He joined the Dutch pharmaceutical company Organon in 1986 and moved to the position of Vice President Research in 2003. After the acquisition of Organon by Schering-Plough in 2007, Ton was appointed VP Discovery and Site Head Oss and continued this position after the merger of Merck and Schering-Plough. In 2011 Ton co-founded TI Pharma, a public-private partnership in drug discovery, and acted as its Scientific Director. He continued this work after the merger of CTMM and TI Pharma into Lygature in 2016. Ton currently holds the position of General Director at Oncode Institute. By combining individual excellence and collaborative development, Oncode works towards innovative cancer treatments. Ton uses his experience to bring together the great minds of cancer research in The Netherlands.

Said Ton of his appointment: "I am thrilled to be a Trustee of AAAMD, a non-profit which continues to accelerate AMD research and challenge the status quo in drug discovery. My sincerest thanks to Rob for welcoming me to the Board. I look forward to working alongside Lee and the entire AAAMD team in their mission to end sight loss caused by AMD."

Said Chair of the Board Rob Bryan: "We are excited to welcome Dr. Ton Rijnders as a Trustee of AAAMD. Ton's extensive experience in collaborative, patient-focused drug discovery make him a fabulous addition to AAAMD's Board."

Said CEO Wen Hwa Lee: "Ton is a long-time collaborator of mine, and I could not be more pleased to welcome him to the Board of Trustees. Ton brings strategic vision, scientific leadership, and decades of experience managing collaborative public-private partnerships to our Board. On behalf of the entire AAAMD team, I would like to extend the warmest of welcomes to Ton. We look forward to working with him for years to come."


bottom of page